Global CD40 Ligand
Global CD40 Ligand

CD40 Ligand Comprehensive Study by Type (ISF-35, LOAd-700, MEDI-4920, MegaCD40L, Other), Application (Hepatitis B, Bladder Cancer, Liver Cancer, Ovarian Cancer, Others) Players and Region - Global Market Outlook to 2024

CD40 Ligand Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Aug 2019 Edition 217 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
The CD40 ligand or CD40 pathway is widely recognized for its prominent role in immune regulation and homeostasis. CD40 is a surface antigen expressed on B cells and the CD40 ligand (CD40L) is expressed on activated T cells. Interaction between CD40 and CD40L is difficult for proliferation and isotype switching in the context of a response to a T-celldependent antigen. Patients with X-linked hyper-IgM syndrome (HIGMX-1) in their CD40L gene are unable to switch from IgM to IgG, IgE and IgA. Mice with a disrupted CD40 gene fail to undergo isotype switching to T-cell-dependent antigens but respond generally to T-independent antigens.This growth is primarily driven by Rising Prevalence of Cancer Worldwide and Government Initiative to Improve Healthcare Services.

Globally, a noticeable market trend is evident Rising Usage of CD40 in Cancer Treatment. Major Players, such as Biogen, Inc. (United States), Bristol-Myers Squibb Company (United States), eTheRNA Immunotherapies NV (Belgium), ImmuNext, Inc. (United States), Juno Therapeutics Inc. (United States), MedImmune, LLC (United States), Targovax AS (Norway), XL-protein GmbH (Germany) and FUJIFILM Irvine Scientific (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On July 26, 2017 - Jazz Pharmaceuticals plc today announced that it has entered into a license agreement with XL-protein GmbH for the rights to develop, manufacture and commercialize products using XLp's PASylation Technology to extend the plasma half-life of selected asparaginase product candidates.

Market Drivers
  • Rising Prevalence of Cancer Worldwide
  • Government Initiative to Improve Healthcare Services

Market Trend
  • Rising Usage of CD40 in Cancer Treatment

Restraints
  • Government Regulations for Protein Therapeutics

Opportunities
Rising Research Activities on CD40 Ligand
Challenges
Lack of Awareness about the Therapeutic Drug Treatment

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • ISF-35
  • LOAd-700
  • MEDI-4920
  • MegaCD40L
  • Other
By Application
  • Hepatitis B
  • Bladder Cancer
  • Liver Cancer
  • Ovarian Cancer
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cancer Worldwide
      • 3.2.2. Government Initiative to Improve Healthcare Services
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about the Therapeutic Drug Treatment
    • 3.4. Market Trends
      • 3.4.1. Rising Usage of CD40 in Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global CD40 Ligand, by Type, Application and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global CD40 Ligand (Value)
      • 5.2.1. Global CD40 Ligand by: Type (Value)
        • 5.2.1.1. ISF-35
        • 5.2.1.2. LOAd-700
        • 5.2.1.3. MEDI-4920
        • 5.2.1.4. MegaCD40L
        • 5.2.1.5. Other
      • 5.2.2. Global CD40 Ligand by: Application (Value)
        • 5.2.2.1. Hepatitis B
        • 5.2.2.2. Bladder Cancer
        • 5.2.2.3. Liver Cancer
        • 5.2.2.4. Ovarian Cancer
        • 5.2.2.5. Others
      • 5.2.3. Global CD40 Ligand Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global CD40 Ligand (Price)
      • 5.3.1. Global CD40 Ligand by: Type (Price)
  • 6. CD40 Ligand: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biogen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ETheRNA Immunotherapies NV (Belgium)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ImmuNext, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Juno Therapeutics Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MedImmune, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Targovax AS (Norway)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. XL-protein GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. FUJIFILM Irvine Scientific (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global CD40 Ligand Sale, by Type, Application and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global CD40 Ligand (Value)
      • 7.2.1. Global CD40 Ligand by: Type (Value)
        • 7.2.1.1. ISF-35
        • 7.2.1.2. LOAd-700
        • 7.2.1.3. MEDI-4920
        • 7.2.1.4. MegaCD40L
        • 7.2.1.5. Other
      • 7.2.2. Global CD40 Ligand by: Application (Value)
        • 7.2.2.1. Hepatitis B
        • 7.2.2.2. Bladder Cancer
        • 7.2.2.3. Liver Cancer
        • 7.2.2.4. Ovarian Cancer
        • 7.2.2.5. Others
      • 7.2.3. Global CD40 Ligand Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global CD40 Ligand (Price)
      • 7.3.1. Global CD40 Ligand by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. CD40 Ligand: by Type(USD Million)
  • Table 2. CD40 Ligand ISF-35 , by Region USD Million (2013-2018)
  • Table 3. CD40 Ligand LOAd-700 , by Region USD Million (2013-2018)
  • Table 4. CD40 Ligand MEDI-4920 , by Region USD Million (2013-2018)
  • Table 5. CD40 Ligand MegaCD40L , by Region USD Million (2013-2018)
  • Table 6. CD40 Ligand Other , by Region USD Million (2013-2018)
  • Table 7. CD40 Ligand: by Application(USD Million)
  • Table 8. CD40 Ligand Hepatitis B , by Region USD Million (2013-2018)
  • Table 9. CD40 Ligand Bladder Cancer , by Region USD Million (2013-2018)
  • Table 10. CD40 Ligand Liver Cancer , by Region USD Million (2013-2018)
  • Table 11. CD40 Ligand Ovarian Cancer , by Region USD Million (2013-2018)
  • Table 12. CD40 Ligand Others , by Region USD Million (2013-2018)
  • Table 13. South America CD40 Ligand, by Country USD Million (2013-2018)
  • Table 14. South America CD40 Ligand, by Type USD Million (2013-2018)
  • Table 15. South America CD40 Ligand, by Application USD Million (2013-2018)
  • Table 16. Brazil CD40 Ligand, by Type USD Million (2013-2018)
  • Table 17. Brazil CD40 Ligand, by Application USD Million (2013-2018)
  • Table 18. Argentina CD40 Ligand, by Type USD Million (2013-2018)
  • Table 19. Argentina CD40 Ligand, by Application USD Million (2013-2018)
  • Table 20. Rest of South America CD40 Ligand, by Type USD Million (2013-2018)
  • Table 21. Rest of South America CD40 Ligand, by Application USD Million (2013-2018)
  • Table 22. Asia Pacific CD40 Ligand, by Country USD Million (2013-2018)
  • Table 23. Asia Pacific CD40 Ligand, by Type USD Million (2013-2018)
  • Table 24. Asia Pacific CD40 Ligand, by Application USD Million (2013-2018)
  • Table 25. China CD40 Ligand, by Type USD Million (2013-2018)
  • Table 26. China CD40 Ligand, by Application USD Million (2013-2018)
  • Table 27. Japan CD40 Ligand, by Type USD Million (2013-2018)
  • Table 28. Japan CD40 Ligand, by Application USD Million (2013-2018)
  • Table 29. India CD40 Ligand, by Type USD Million (2013-2018)
  • Table 30. India CD40 Ligand, by Application USD Million (2013-2018)
  • Table 31. South Korea CD40 Ligand, by Type USD Million (2013-2018)
  • Table 32. South Korea CD40 Ligand, by Application USD Million (2013-2018)
  • Table 33. Taiwan CD40 Ligand, by Type USD Million (2013-2018)
  • Table 34. Taiwan CD40 Ligand, by Application USD Million (2013-2018)
  • Table 35. Australia CD40 Ligand, by Type USD Million (2013-2018)
  • Table 36. Australia CD40 Ligand, by Application USD Million (2013-2018)
  • Table 37. Rest of Asia-Pacific CD40 Ligand, by Type USD Million (2013-2018)
  • Table 38. Rest of Asia-Pacific CD40 Ligand, by Application USD Million (2013-2018)
  • Table 39. Europe CD40 Ligand, by Country USD Million (2013-2018)
  • Table 40. Europe CD40 Ligand, by Type USD Million (2013-2018)
  • Table 41. Europe CD40 Ligand, by Application USD Million (2013-2018)
  • Table 42. Germany CD40 Ligand, by Type USD Million (2013-2018)
  • Table 43. Germany CD40 Ligand, by Application USD Million (2013-2018)
  • Table 44. France CD40 Ligand, by Type USD Million (2013-2018)
  • Table 45. France CD40 Ligand, by Application USD Million (2013-2018)
  • Table 46. Italy CD40 Ligand, by Type USD Million (2013-2018)
  • Table 47. Italy CD40 Ligand, by Application USD Million (2013-2018)
  • Table 48. United Kingdom CD40 Ligand, by Type USD Million (2013-2018)
  • Table 49. United Kingdom CD40 Ligand, by Application USD Million (2013-2018)
  • Table 50. Netherlands CD40 Ligand, by Type USD Million (2013-2018)
  • Table 51. Netherlands CD40 Ligand, by Application USD Million (2013-2018)
  • Table 52. Rest of Europe CD40 Ligand, by Type USD Million (2013-2018)
  • Table 53. Rest of Europe CD40 Ligand, by Application USD Million (2013-2018)
  • Table 54. MEA CD40 Ligand, by Country USD Million (2013-2018)
  • Table 55. MEA CD40 Ligand, by Type USD Million (2013-2018)
  • Table 56. MEA CD40 Ligand, by Application USD Million (2013-2018)
  • Table 57. Middle East CD40 Ligand, by Type USD Million (2013-2018)
  • Table 58. Middle East CD40 Ligand, by Application USD Million (2013-2018)
  • Table 59. Africa CD40 Ligand, by Type USD Million (2013-2018)
  • Table 60. Africa CD40 Ligand, by Application USD Million (2013-2018)
  • Table 61. North America CD40 Ligand, by Country USD Million (2013-2018)
  • Table 62. North America CD40 Ligand, by Type USD Million (2013-2018)
  • Table 63. North America CD40 Ligand, by Application USD Million (2013-2018)
  • Table 64. United States CD40 Ligand, by Type USD Million (2013-2018)
  • Table 65. United States CD40 Ligand, by Application USD Million (2013-2018)
  • Table 66. Canada CD40 Ligand, by Type USD Million (2013-2018)
  • Table 67. Canada CD40 Ligand, by Application USD Million (2013-2018)
  • Table 68. Mexico CD40 Ligand, by Type USD Million (2013-2018)
  • Table 69. Mexico CD40 Ligand, by Application USD Million (2013-2018)
  • Table 70. CD40 Ligand: by Type(USD/Units)
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. CD40 Ligand: by Type(USD Million)
  • Table 81. CD40 Ligand ISF-35 , by Region USD Million (2019-2024)
  • Table 82. CD40 Ligand LOAd-700 , by Region USD Million (2019-2024)
  • Table 83. CD40 Ligand MEDI-4920 , by Region USD Million (2019-2024)
  • Table 84. CD40 Ligand MegaCD40L , by Region USD Million (2019-2024)
  • Table 85. CD40 Ligand Other , by Region USD Million (2019-2024)
  • Table 86. CD40 Ligand: by Application(USD Million)
  • Table 87. CD40 Ligand Hepatitis B , by Region USD Million (2019-2024)
  • Table 88. CD40 Ligand Bladder Cancer , by Region USD Million (2019-2024)
  • Table 89. CD40 Ligand Liver Cancer , by Region USD Million (2019-2024)
  • Table 90. CD40 Ligand Ovarian Cancer , by Region USD Million (2019-2024)
  • Table 91. CD40 Ligand Others , by Region USD Million (2019-2024)
  • Table 92. South America CD40 Ligand, by Country USD Million (2019-2024)
  • Table 93. South America CD40 Ligand, by Type USD Million (2019-2024)
  • Table 94. South America CD40 Ligand, by Application USD Million (2019-2024)
  • Table 95. Brazil CD40 Ligand, by Type USD Million (2019-2024)
  • Table 96. Brazil CD40 Ligand, by Application USD Million (2019-2024)
  • Table 97. Argentina CD40 Ligand, by Type USD Million (2019-2024)
  • Table 98. Argentina CD40 Ligand, by Application USD Million (2019-2024)
  • Table 99. Rest of South America CD40 Ligand, by Type USD Million (2019-2024)
  • Table 100. Rest of South America CD40 Ligand, by Application USD Million (2019-2024)
  • Table 101. Asia Pacific CD40 Ligand, by Country USD Million (2019-2024)
  • Table 102. Asia Pacific CD40 Ligand, by Type USD Million (2019-2024)
  • Table 103. Asia Pacific CD40 Ligand, by Application USD Million (2019-2024)
  • Table 104. China CD40 Ligand, by Type USD Million (2019-2024)
  • Table 105. China CD40 Ligand, by Application USD Million (2019-2024)
  • Table 106. Japan CD40 Ligand, by Type USD Million (2019-2024)
  • Table 107. Japan CD40 Ligand, by Application USD Million (2019-2024)
  • Table 108. India CD40 Ligand, by Type USD Million (2019-2024)
  • Table 109. India CD40 Ligand, by Application USD Million (2019-2024)
  • Table 110. South Korea CD40 Ligand, by Type USD Million (2019-2024)
  • Table 111. South Korea CD40 Ligand, by Application USD Million (2019-2024)
  • Table 112. Taiwan CD40 Ligand, by Type USD Million (2019-2024)
  • Table 113. Taiwan CD40 Ligand, by Application USD Million (2019-2024)
  • Table 114. Australia CD40 Ligand, by Type USD Million (2019-2024)
  • Table 115. Australia CD40 Ligand, by Application USD Million (2019-2024)
  • Table 116. Rest of Asia-Pacific CD40 Ligand, by Type USD Million (2019-2024)
  • Table 117. Rest of Asia-Pacific CD40 Ligand, by Application USD Million (2019-2024)
  • Table 118. Europe CD40 Ligand, by Country USD Million (2019-2024)
  • Table 119. Europe CD40 Ligand, by Type USD Million (2019-2024)
  • Table 120. Europe CD40 Ligand, by Application USD Million (2019-2024)
  • Table 121. Germany CD40 Ligand, by Type USD Million (2019-2024)
  • Table 122. Germany CD40 Ligand, by Application USD Million (2019-2024)
  • Table 123. France CD40 Ligand, by Type USD Million (2019-2024)
  • Table 124. France CD40 Ligand, by Application USD Million (2019-2024)
  • Table 125. Italy CD40 Ligand, by Type USD Million (2019-2024)
  • Table 126. Italy CD40 Ligand, by Application USD Million (2019-2024)
  • Table 127. United Kingdom CD40 Ligand, by Type USD Million (2019-2024)
  • Table 128. United Kingdom CD40 Ligand, by Application USD Million (2019-2024)
  • Table 129. Netherlands CD40 Ligand, by Type USD Million (2019-2024)
  • Table 130. Netherlands CD40 Ligand, by Application USD Million (2019-2024)
  • Table 131. Rest of Europe CD40 Ligand, by Type USD Million (2019-2024)
  • Table 132. Rest of Europe CD40 Ligand, by Application USD Million (2019-2024)
  • Table 133. MEA CD40 Ligand, by Country USD Million (2019-2024)
  • Table 134. MEA CD40 Ligand, by Type USD Million (2019-2024)
  • Table 135. MEA CD40 Ligand, by Application USD Million (2019-2024)
  • Table 136. Middle East CD40 Ligand, by Type USD Million (2019-2024)
  • Table 137. Middle East CD40 Ligand, by Application USD Million (2019-2024)
  • Table 138. Africa CD40 Ligand, by Type USD Million (2019-2024)
  • Table 139. Africa CD40 Ligand, by Application USD Million (2019-2024)
  • Table 140. North America CD40 Ligand, by Country USD Million (2019-2024)
  • Table 141. North America CD40 Ligand, by Type USD Million (2019-2024)
  • Table 142. North America CD40 Ligand, by Application USD Million (2019-2024)
  • Table 143. United States CD40 Ligand, by Type USD Million (2019-2024)
  • Table 144. United States CD40 Ligand, by Application USD Million (2019-2024)
  • Table 145. Canada CD40 Ligand, by Type USD Million (2019-2024)
  • Table 146. Canada CD40 Ligand, by Application USD Million (2019-2024)
  • Table 147. Mexico CD40 Ligand, by Type USD Million (2019-2024)
  • Table 148. Mexico CD40 Ligand, by Application USD Million (2019-2024)
  • Table 149. CD40 Ligand: by Type(USD/Units)
  • Table 150. Research Programs/Design for This Report
  • Table 151. Key Data Information from Secondary Sources
  • Table 152. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global CD40 Ligand: by Type USD Million (2013-2018)
  • Figure 5. Global CD40 Ligand: by Application USD Million (2013-2018)
  • Figure 6. South America CD40 Ligand Share (%), by Country
  • Figure 7. Asia Pacific CD40 Ligand Share (%), by Country
  • Figure 8. Europe CD40 Ligand Share (%), by Country
  • Figure 9. MEA CD40 Ligand Share (%), by Country
  • Figure 10. North America CD40 Ligand Share (%), by Country
  • Figure 11. Global CD40 Ligand: by Type USD/Units (2013-2018)
  • Figure 12. Global CD40 Ligand share by Players 2018 (%)
  • Figure 13. Global CD40 Ligand share by Players (Top 3) 2018(%)
  • Figure 14. Global CD40 Ligand share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Biogen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Biogen, Inc. (United States) Revenue: by Geography 2018
  • Figure 18. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 20. ETheRNA Immunotherapies NV (Belgium) Revenue, Net Income and Gross profit
  • Figure 21. ETheRNA Immunotherapies NV (Belgium) Revenue: by Geography 2018
  • Figure 22. ImmuNext, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. ImmuNext, Inc. (United States) Revenue: by Geography 2018
  • Figure 24. Juno Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Juno Therapeutics Inc. (United States) Revenue: by Geography 2018
  • Figure 26. MedImmune, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 27. MedImmune, LLC (United States) Revenue: by Geography 2018
  • Figure 28. Targovax AS (Norway) Revenue, Net Income and Gross profit
  • Figure 29. Targovax AS (Norway) Revenue: by Geography 2018
  • Figure 30. XL-protein GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 31. XL-protein GmbH (Germany) Revenue: by Geography 2018
  • Figure 32. FUJIFILM Irvine Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 33. FUJIFILM Irvine Scientific (United States) Revenue: by Geography 2018
  • Figure 34. Global CD40 Ligand: by Type USD Million (2019-2024)
  • Figure 35. Global CD40 Ligand: by Application USD Million (2019-2024)
  • Figure 36. South America CD40 Ligand Share (%), by Country
  • Figure 37. Asia Pacific CD40 Ligand Share (%), by Country
  • Figure 38. Europe CD40 Ligand Share (%), by Country
  • Figure 39. MEA CD40 Ligand Share (%), by Country
  • Figure 40. North America CD40 Ligand Share (%), by Country
  • Figure 41. Global CD40 Ligand: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Biogen, Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • eTheRNA Immunotherapies NV (Belgium)
  • ImmuNext, Inc. (United States)
  • Juno Therapeutics Inc. (United States)
  • MedImmune, LLC (United States)
  • Targovax AS (Norway)
  • XL-protein GmbH (Germany)
  • FUJIFILM Irvine Scientific (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation